Eli Lilly (LLY) EBITDA Margin (2009 - 2026)
Eli Lilly (LLY) recorded EBITDA Margin of 53.49% in Q2 2026, up 5.29 percentage points from 48.20% a year earlier and up 2.94 percentage points from the prior quarter.
Eli Lilly (LLY) EBITDA Margin (2009 - 2026) Analysis & Trends
On a TTM basis, Eli Lilly's EBITDA Margin came in at 50.56% as of Jun 30, 2026, up 5.74 percentage points year-over-year; for FY2025, it was 47.88%, up 8.04 percentage points from FY2024.
- Annual EBITDA Margin has increased for four straight years, with a five-year change of +14.66 percentage points (FY2020 to FY2025).
- Across earlier years, EBITDA Margin came in at 39.84% in FY2024 (+5.31 pp), 34.53% in FY2023 (+1.04 pp), 33.49% in FY2022 (+2.15 pp) and 31.34% in FY2021 (-1.88 pp).
- The Q2 2026 figure is the highest quarterly EBITDA Margin in data going back to Q1 2009.
- On a year-over-year basis, EBITDA Margin has increased for 13 consecutive quarters, with an average year-over-year change of +6.55 percentage points over the last eight quarters.
- Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 11.78 percentage points in Q1 2022, against a drop of 10.30 percentage points in Q1 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at 50.55% (Q1 2026), 49.19% (Q4 2025) and 48.24% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,146.94 Bn | 1,115.53 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 624.96 Bn | 543.49 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 510.15 Bn | 483.27 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 366.13 Bn | 320.51 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 297.75 Bn | 261.74 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.93 Bn | 235.62 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 236.51 Bn | 191.91 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 194.27 Bn | 168.47 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 171.74 Bn | 118.39 Bn | 10.94 Bn | 39.16% |
| 10 | Vertex Pharmaceuticals | 130.00 Bn | 102.01 Bn | 2.84 Bn | 39.10% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 53.49% |
| Mar 31, 2026 | 50.55% |
| Dec 31, 2025 | 49.19% |
| Sep 30, 2025 | 48.24% |
| Jun 30, 2025 | 48.20% |
| Mar 31, 2025 | 45.02% |
| Dec 31, 2024 | 43.03% |
| Sep 30, 2024 | 42.13% |
| Jun 30, 2024 | 37.90% |
| Mar 31, 2024 | 34.44% |
| Dec 31, 2023 | 36.32% |
| Sep 30, 2023 | 40.39% |
| Jun 30, 2023 | 31.15% |
| Mar 31, 2023 | 28.18% |
| Dec 31, 2022 | 33.57% |
| Sep 30, 2022 | 30.28% |
| Jun 30, 2022 | 30.82% |
| Mar 31, 2022 | 38.48% |
| Dec 31, 2021 | 35.01% |
| Sep 30, 2021 | 36.04% |
Eli Lilly EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=LLY&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "LLY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=LLY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();